In this article

LLY

MTSR

NOVO.B-DK

PFE

Follow your favorite stocks CREATE FREE ACCOUNT

President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs , including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments.

The agreements will cut prices of so-called GLP-1 drugs for Medicare and Medicaid beneficiaries in 2026 and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January called TrumpRx.gov.

That means Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more p

See Full Page